Efficacy of folic acid supplementation in cardiovascular disease prevention: an updated meta-analysis of randomized controlled trials.

[1]  P. Galan,et al.  Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial , 2010, BMJ : British Medical Journal.

[2]  G. Hankey.  B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial , 2010, The Lancet Neurology.

[3]  R. Collins,et al.  Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. , 2010, JAMA.

[4]  D. Churchill,et al.  Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. , 2010, JAMA.

[5]  J. Heinz,et al.  B Vitamins and the Risk of Total Mortality and Cardiovascular Disease in End-Stage Renal Disease: Results of a Randomized Controlled Trial , 2010, Circulation.

[6]  S. Condello,et al.  Homocysteine-induced toxicity increases TG2 expression in Neuro2a cells , 2009, Amino Acids.

[7]  M. Imasa,et al.  Folic Acid-Based Intervention in Non-ST Elevation Acute Coronary Syndromes , 2009, Asian cardiovascular & thoracic annals.

[8]  D. Levy,et al.  Multimarker Approach to Evaluate Correlates of Vascular Stiffness: The Framingham Heart Study , 2009, Circulation.

[9]  J. Manson,et al.  Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. , 2008, JAMA.

[10]  F. Fallani,et al.  Long-Term Effect of Folic Acid Therapy in Heart Transplant Recipients: Follow-Up Analysis of a Randomized Study , 2008, Transplantation.

[11]  P. Guarino,et al.  Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. , 2007, JAMA.

[12]  M. Robson,et al.  Global Improvement of Vascular Function and Redox State With Low-Dose Folic Acid: Implications for Folate Therapy in Patients With Coronary Artery Disease , 2007, Circulation.

[13]  T. Matsuo,et al.  Uremic hyperhomocysteinemia: A randomized trial of folate treatment for the prevention of cardiovascular events , 2007, Hemodialysis international. International Symposium on Home Hemodialysis.

[14]  R. Hui,et al.  Hyperhomocysteinemia Decreases Circulating High-Density Lipoprotein by Inhibiting Apolipoprotein A-I Protein Synthesis and Enhancing HDL Cholesterol Clearance , 2006, Circulation research.

[15]  S. Yusuf,et al.  Homocysteine lowering with folic acid and B vitamins in vascular disease. , 2006, The New England journal of medicine.

[16]  Per Magne Ueland,et al.  Homocysteine lowering and cardiovascular events after acute myocardial infarction. , 2006, The New England journal of medicine.

[17]  T. Marwick,et al.  Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease , 2006, Heart.

[18]  Raimund Erbel,et al.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.

[19]  G. Beck,et al.  Relationship Between Homocysteine and Mortality in Chronic Kidney Disease , 2006, Circulation.

[20]  J. McNeil,et al.  Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. , 2006, Journal of the American College of Cardiology.

[21]  R. Berry,et al.  Improvement in Stroke Mortality in Canada and the United States, 1990 to 2002 , 2006, Circulation.

[22]  R. Rozen,et al.  Elevated Homocysteine Reduces Apolipoprotein A-I Expression in Hyperhomocysteinemic Mice and in Males With Coronary Artery Disease , 2006, Circulation research.

[23]  A. Zwinderman,et al.  Secondary prevention with folic acid: results of the Goes extension study , 2005, Heart.

[24]  H. Suryapranata,et al.  Folate therapy and in-stent restenosis after coronary stenting. , 2004, The New England journal of medicine.

[25]  K. Yamagishi,et al.  Serum Total Homocysteine Concentrations and Risk of Stroke and Its Subtypes in Japanese , 2004, Circulation.

[26]  L. Chambless,et al.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. , 2004, JAMA.

[27]  J. Zehnder,et al.  Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. , 2004, Journal of the American Society of Nephrology : JASN.

[28]  J. Tijssen,et al.  Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial. , 2004, International journal of cardiology.

[29]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[30]  A. Zwinderman,et al.  Secondary prevention with folic acid: effects on clinical outcomes. , 2003, Journal of the American College of Cardiology.

[31]  A. Sessa,et al.  Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. , 2003, Medical science monitor : international medical journal of experimental and clinical research.

[32]  Per Magne Ueland,et al.  Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. , 2002, JAMA.

[33]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[34]  J. Sterne,et al.  Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. , 2001, Journal of clinical epidemiology.

[35]  D. Qujeq,et al.  Correlation between total homocysteine, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in the serum of patients with myocardial infarction. , 2001, Clinical biochemistry.

[36]  J. Twisk,et al.  Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial , 2000, The Lancet.

[37]  I. Olkin,et al.  Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.

[38]  J. Loscalzo,et al.  Homocysteine and atherothrombosis. , 1998, The New England journal of medicine.

[39]  D. Wilcken,et al.  The natural history of vascular disease in homocystinuria and the effects of treatment , 1997, Journal of Inherited Metabolic Disease.

[40]  P. Wilson,et al.  Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. , 1996, JAMA.

[41]  J. Fraumeni,et al.  Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: the Linxian Nutrition Intervention Trial. , 1996, American journal of epidemiology.

[42]  S. Henning,et al.  Homocysteine increases as folate decreases in plasma of healthy men during short-term dietary folate and methyl group restriction. , 1994, The Journal of nutrition.

[43]  J M Robins,et al.  Estimation of a common effect parameter from sparse follow-up data. , 1985, Biometrics.

[44]  K. Mccully.  Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. , 1969, The American journal of pathology.

[45]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[46]  R. Garrick.  Homocysteine-Lowering and Cardiovascular Disease Outcomes in Kidney Transplant Recipients: Primary Results From the Folic Acid for Vascular Outcome Reduction in Transplantation Trial , 2011 .

[47]  G. Moneta.  High-Dose B Vitamin Supplementation and Progression of Subclinical Atherosclerosis: A Randomized Controlled Trial , 2010 .

[48]  Georgia Salanti,et al.  Homocysteine lowering interventions for preventing cardiovascular events. , 2009, The Cochrane database of systematic reviews.

[49]  J. Twisk,et al.  Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[50]  S. Vollset,et al.  Angiography : A Randomized Controlled Trial CoronaryWith Homocysteine-Lowering B Vitamins After Mortality and Cardiovascular Events in Patients Treated , 2008 .

[51]  M. Righetti.  Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients , 2007, Clinical chemistry and laboratory medicine.

[52]  Hugh S Markus,et al.  Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. , 2004, Brain : a journal of neurology.

[53]  O. Hess,et al.  Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention. the swiss heart study: a randomized controlled trial☆ , 2003 .

[54]  J. Manson,et al.  Homocysteine and risk of cardiovascular disease among postmenopausal women. , 1999, JAMA.